J Donald Siegrist, MD | |
29 Eastbrook Rd, Ronks, PA 17572-9769 | |
(717) 299-5711 | |
Not Available |
Full Name | J Donald Siegrist |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 29 Eastbrook Rd, Ronks, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659313682 | NPI | - | NPPES |
0643207 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD034918L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
J Donald Siegrist, MD 29 Eastbrook Rd, Ronks, PA 17572-9769 Ph: (717) 299-5711 | J Donald Siegrist, MD 29 Eastbrook Rd, Ronks, PA 17572-9769 Ph: (717) 299-5711 |
News Archive
St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers.
Women's reports of persistent, recent-onset symptoms linked to ovarian cancer - abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating - when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent, according to new findings by researchers at Fred Hutchinson Cancer Research Center published online today in CANCER.
Since its first outbreak in Guinea in December, 2013, Ebola has hit West African healthcare providers disproportionately hard.
EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.
Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat.
› Verified 6 days ago
Dr. Chris Paul Lupold, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 334 Hartman Bridge Rd, Ronks, PA 17572 Phone: 717-925-8469 Fax: 717-983-4722 | |
Richard D Jackson, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 29 Eastbrook Rd, Ronks, PA 17572 Phone: 717-299-5711 | |
James G Duprey, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 29 Eastbrook Rd, Ronks, PA 17572 Phone: 717-299-5711 | |
John Clair Hess, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 29 Eastbrook Rd, Ronks, PA 17572 Phone: 717-299-5711 |